Wire · opportunities
Teva wins FDA nod for monthly olanzapine shot that ends monitoring
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 October 2026 · Fusion42 review
Teva's new long-acting subcutaneous olanzapine injection, Weltruza, has gained FDA approval to treat adult schizophrenia without needing post-injection monitoring, contrasting with existing injections that require patient observation due to safety risks.
This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it between 9 Oct 2026 and 13 Oct 2026.
◆ ◆ The Wire takeaway
You can now offer schizophrenia treatment that improves patient adherence by eliminating the costly monitoring period after injections. Teva's subcutaneous shot opens a simpler path to market for long-acting psychiatric drugs that avoid existing safety hurdles.
◆ Coverage
20 sources · first reported 9 Oct 2026 · latest 13 Oct 2026
◆ Topics